A novel and simple type of liposome carrier for recombinant interleukin-2
- 1 March 2001
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 53 (3) , 295-302
- https://doi.org/10.1211/0022357011775523
Abstract
The strong interaction between recombinant interleukin-2 (IL-2) and liposome was characterized and its possible application to drug-delivery control considered. The liposomes were prepared with egg phosphatidylcholine, distearoyl-phosphatidylglycerol (DSPG), dipalmitoyl-phosphatidylcholine, dipalmitoyl-phosphatidylglycerol or distearoyl-phosphatidylcholine (DSPC). Small and hydrophobic liposomes were selected, which were composed of saturated and long-fatty-acid-chain phospholipids. When the composition and the mixture ratio of IL-2 and the liposome were optimized, more than 95% of the lyophilized IL-2 (Imunace, 350000, JRU) was adsorbed consistently onto the DSPC-DSPG liposome (molar ratio, 10:1; 25 μmol mL−1; 30 nm in size). Merely mixing IL-2 lyophilized with liposome suspension is convenient pharmaceutically. After intravenous administration to mice, liposomal IL-2 was eliminated half as slowly from the systemic circulation as free IL-2, with more than 13 and 18 times more IL-2 being delivered to the liver and spleen, respectively. After subcutaneous administration of liposomal IL-2 to mice, the mean residence time of IL-2 in the systemic circulation was 8 times that of free IL-2. These results show that IL-2 consistently adsorbs onto the surface of liposomes after optimization of its composition and mixing ratio. Intravenous and subcutaneous administration to mice demonstrates the gradual release of IL-2. Further trials are warranted using these liposomes.Keywords
This publication has 24 references indexed in Scilit:
- Stabilization of aerosolized IFN-γ by liposomesInternational Journal of Pharmaceutics, 1999
- Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastasesCancer, 1997
- Section Review: Biologicals & Immunologicals: Immunotherapy with interleukin-2: Recent developmentsExpert Opinion on Investigational Drugs, 1996
- Reevaluation of the Superiority of Polyethylene GlycolModified Interleukin-2 Over Regular Recombinant Interleukin-2Journal of Interferon & Cytokine Research, 1995
- Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized LiposomesJournal of Immunotherapy, 1994
- Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2Clinical Pharmacokinetics, 1994
- The role of protein charge in protein-lipid interactions. pH-Dependent changes of the electrophoretic mobility of liposomes through adsorption of water-soluble, globular proteinsBiochemistry, 1993
- Interleukin-2-Containing Liposomes: Interaction of Interleukin-2 with Liposomal Bilayers and Preliminary Studies on Application in Cancer VaccinesPharmaceutical Research, 1993
- Interleukin-2 in liposomes: Increased intravenous potency and less pulmonary toxicity in the ratDrug Development Research, 1992
- Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.Proceedings of the National Academy of Sciences, 1987